SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 3

Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels (Editöre Mektup)

Koroner arter hastalığının ikincil korunması için gün aşırı statin dozu/Günaşırı 20 mg atorvastatin tedavisinin serum LDL-kolesterolü ve düksek duyarlı C-reaktif protein düzeyleri üzerine etkisinin günlük 20 mg atorvastatin tedavisi ile karşılaştırılması (Letters to the Editor)

Turgay ÇELİK
Murat ÇELİK
Pages
253–254
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

ÇELİK, T., ÇELİK, M. (2022). Alternate-day dosing of statins for secondary prevention of coronary artery disease/The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels (Editöre Mektup). Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 3, 253–254. https://ajindex.com/articles/436887

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Keleş T, Bayram NA, Kayhan T, Canbay A, Sahin D, Durmaz T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Anadolu Kardiyol Derg 2008; 6: 407-12
  2. Buller N, Gillen D, Casciano R, Doyle J, Wilson K. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003; 21 Suppl 1: 25-32
  3. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80
  4. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405-10
  5. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006; 97: 1553-7.